Albireo to Participate in 2022 Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the 2022 Wedbush PacGrow Healthcare Conference August 9-10, 2022. Ron Cooper, President and Chief Executive Officer of Albireo, will be presenting on August 9, 2022. A replay of the webcast will be available on-demand on the Albireo Investors page ir.albireopharma.com. Ron and Simon Harford, Chief Financial Officer, will host meetings with investors.

About Albireo

Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe, Bylvay has been approved for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with global Phase 3 trials in Alagille syndrome (ALGS) and biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com

Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578

Staff

Recent Posts

Alzheon Raises $100 Million Series E Financing Round to Advance Development and Commercialization of Oral Tablet ALZ-801/Valiltramiprosate for Treatment of Alzheimer’s Disease

Proceeds Will Support Completion of Pivotal APOLLOE4 Phase 3 Study Evaluating ALZ-801/Valiltramiprosate and Regulatory Filings…

24 mins ago

Twenty Percent Of The World’s Employees Experience Loneliness While Global Employee Engagement Stagnated And Employee Wellbeing Declined

WASHINGTON, June 12, 2024 /PRNewswire/ -- Gallup's latest State of the Global Workplace report finds that…

27 mins ago

Alida Biosciences Announces Series A Funding and Early Access Launch of Innovative Products for Epitranscriptomic Research

SAN DIEGO, June 12, 2024 /PRNewswire/ -- Alida Biosciences (AlidaBio), an innovator in epigenomic research tools,…

27 mins ago

ScandiNova joins the United Nations Global Compact

UPPSALA, Sweden, June 12, 2024 /PRNewswire/ -- ScandiNova Group is proud to announce its participation…

27 mins ago